[SKF 93479, a newly developed histamine H2-receptor antagonist. / Effect on gastric potential difference in the presence and absence of acetylsalicylic acid].
Acetylsalicylic acid (ASA) alters the gastric mucosal barrier as measured by the transmucosal potential difference (PD). The effect of the newly developed histamine H2-receptor antagonist 2-(2-(5-dimethylaminoethylfuran-2-ylmethylthio)ethylamino)-5-(6-methylpyrid-3-ylmethyl)pyrimid-4-one trihydrochloride (SKF 93479) on the ASA-induced drop in gastric PD was studied in 6 healthy volunteers. Mean basal PD was -38.5 to -39.5 mV. After 1000 mg of ASA PD decreased in 10-15 min to -25 mV. In subjects pretreated orally with 0.5 mg/kg SKF 93479, PD rose during 30-45 min to -53.5 mV. After ASA PD fell to -38.5 mV, but did not fall below normal.
D000328:Adult; D001241:Aspirin / Q000494:pharmacology*; D005744:Gastric Acid / Q000378:metabolism; D005753:Gastric Mucosa / Q000187:drug effects*; D006635:Histamine H2 Antagonists / Q000494:pharmacology*; D006801:Humans; D008297:Male; D008564:Membrane Potentials / Q000187:drug effects; D011744:Pyrimidinones / Q000494:pharmacology*; D013997:Time Factors
D006635:Histamine H2 Antagonists; D011744:Pyrimidinones; C033275:SK&F 93479; D001241:Aspirin
SKF 93479, ein neu entwickelter Histamin H2-Rezeptor Antagonist. Wirkung auf die gastrale Potentialdifferenz in An- und Abwesenheit von Acetylsalicylsäure.